An Unforgettable Night of Sufi Magic
Reading Time: 3 minutes iluzn Club & Kitchen, Gurugram’s premier destination for immersive nightlife, is thrilled to announce “Bismil Ki Mehfil,” an unforgettable night featuring the one and only Bismil, on Saturday, 9th November, from 10:30 PM onwards. The event serves as an exclusive afterparty for Bismil’s highly successful
Kesko updates its sustainability strategy
Reading Time: 3 minutes Kesko has updated its sustainability strategy, setting emission reduction targets for its own operations extending to 2034. Over the next 10 years, Kesko will be increasing its investments in energy efficiency and the electrification of transports in an effort to reduce emissions.
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Reading Time: 11 minutes San Mateo, Calif., United States: Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 Oral presentation highlights
DUG Foodtech announces the outcome of the rights issue
Reading Time: 7 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR
Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award
Reading Time: 3 minutes Abu Dhabi, United Arab Emirates: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1 million Human
BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA
Reading Time: 2 minutes Stockholm, November 5, 2024: Immedica announces today that the Biologics License Application (BLA) for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) has been successfully validated and accepted for priority review by the U.S. Food and Drug Administration (FDA). Anders
Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial
Reading Time: 3 minutes Diamyd Medical has entered a strategic partnership with INNODIA, an international non-profit organization dedicated to advancing research on disease modifying therapies for Type 1 Diabetes. The partnership will leverage INNODIA’s extensive EU-based clinical network with the aim to further amplify patient enrolment
SOFTSWISS Wins SBC Latinoamérica Award for Help Brazil Initiative
Reading Time: 2 minutes SOFTSWISS has won the Socially Responsible Initiative of the Year nomination at the SBC Awards Latinoamérica 2024 for its impactful ‘Help Brazil’ initiative. This recognition underscores the company’s support for Brazilian communities affected by severe flooding earlier this year and its dedication to
DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed
Reading Time: 3 minutes The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 7 October 2024 has been completed today, 5 November 2024, following expiry of a 4-week notice period (“proklama”). As set out in press release published
Noble Corporation plc Provides Guidance
Reading Time: < 1 minute SUGAR LAND, TEXAS, Nov. 5, 2024 /PRNewswire/ – Noble Corporation plc (“Noble”) (CSE: NOBLE, NYSE: NE) today provides guidance for the quarter ended December 31, 2024. In accordance with Danish legal and stock exchange requirements, Noble announced that for the quarter